This study is in progress, not accepting new patients
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Matthew Freeby
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Matthew Freeby
HS Associate Clinical Professor, Medicine. Authored (or co-authored) 31 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novo Nordisk A/S
- ID
- NCT03811561
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 1500 study participants
- Last Updated